GlassScriptPhysician profile
Alakananda Chakrabarty
NPI 1205808151
$13,241.78
in general payments reported to CMS, 2019-2025
51 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,301 · 2020: $1,539 · 2021: $1,631 · 2022: $2,013 · 2023: $1,715 · 2024: $1,826 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,752 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,751.65 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,635.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,808.47 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,391.77 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $769.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $725.57 | 2019-2025 | Jardiance, Tradjenta, Combivent Respimat |
| Lilly USA, LLC | $705.71 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Abbvie INC. | $596.38 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $407.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $375.34 | 2019-2023 | |
| Glaxosmithkline, LLC. | $304.68 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $292.49 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.77 | 2019-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $228.07 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $222.33 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $212.87 | 2019-2023 | Eliquis, Camzyos |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alakananda Chakrabarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.